High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: preliminary data of a phase-II study. 1988

G A Nagel, and W Rauschning, and A Ammon, and J H Beyer, and D Emrich, and W Holtkamp, and M Kneba, and H Luig, and N Marschner, and C Unger
Department of Internal Medicine, University Hospital Göttingen.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

G A Nagel, and W Rauschning, and A Ammon, and J H Beyer, and D Emrich, and W Holtkamp, and M Kneba, and H Luig, and N Marschner, and C Unger
August 1990, Onkologie,
G A Nagel, and W Rauschning, and A Ammon, and J H Beyer, and D Emrich, and W Holtkamp, and M Kneba, and H Luig, and N Marschner, and C Unger
January 1994, European journal of cancer (Oxford, England : 1990),
G A Nagel, and W Rauschning, and A Ammon, and J H Beyer, and D Emrich, and W Holtkamp, and M Kneba, and H Luig, and N Marschner, and C Unger
October 1995, Australian and New Zealand journal of medicine,
G A Nagel, and W Rauschning, and A Ammon, and J H Beyer, and D Emrich, and W Holtkamp, and M Kneba, and H Luig, and N Marschner, and C Unger
December 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
G A Nagel, and W Rauschning, and A Ammon, and J H Beyer, and D Emrich, and W Holtkamp, and M Kneba, and H Luig, and N Marschner, and C Unger
January 1996, Cancer chemotherapy and pharmacology,
G A Nagel, and W Rauschning, and A Ammon, and J H Beyer, and D Emrich, and W Holtkamp, and M Kneba, and H Luig, and N Marschner, and C Unger
October 2004, British journal of cancer,
G A Nagel, and W Rauschning, and A Ammon, and J H Beyer, and D Emrich, and W Holtkamp, and M Kneba, and H Luig, and N Marschner, and C Unger
August 1989, International journal of clinical pharmacology, therapy, and toxicology,
G A Nagel, and W Rauschning, and A Ammon, and J H Beyer, and D Emrich, and W Holtkamp, and M Kneba, and H Luig, and N Marschner, and C Unger
January 1996, European journal of cancer (Oxford, England : 1990),
G A Nagel, and W Rauschning, and A Ammon, and J H Beyer, and D Emrich, and W Holtkamp, and M Kneba, and H Luig, and N Marschner, and C Unger
January 2004, Anticancer research,
G A Nagel, and W Rauschning, and A Ammon, and J H Beyer, and D Emrich, and W Holtkamp, and M Kneba, and H Luig, and N Marschner, and C Unger
September 1995, Breast cancer research and treatment,
Copied contents to your clipboard!